Navigation Links
Novel drug holds promise for treatment of Rheumatoid Arthritis

The successful completion of Phase II clinical trials of a novel drug called dnaJP1 for treatment of osteoarthritis that works without suppressing the immune system has been announced by Researchers at the University of California//.

Rheumatoid arthritis is a chronic, painful disease affecting millions worldwide. It is thrice more common in women in men and affects people of any age. It strikes joints on both sides of the body, such as the hands or feet or knees but can also affect the skin, eyes, lungs, heart, blood, nerves or kidneys. It is an incurable disease, with most therapies focusing on symptom relief.

Current medications for treating RA range from anti-inflammatory drugs, such as aspirin, to corticosteroids and medicines that alleviate symptoms by suppressing or killing the body’s immune response, basically crippling the body’s ability to defend itself against other infectious diseases or cancer.

The novel drug is a peptide derived from a naturally occurring protein, dnaJ, which generates inflammation in RA patients. The drug when administered disturbs the immune system, which is then activated to kill and clear foreign pathogens in the body. This results in an enhanced immune response which is not possible otherwise. The drug would have to administered through the oral route as the immune set up in the gut has the potential to educate the body to view a protein as one that isn’t dangerous or foreign. DnaJP1 was found effective in a double-blind, placebo-controlled trial sponsored by the National Institutes of Health, which took place between 2000 and 2005 and involved about 160 patients.

Patients received 25mg of dnaJP1 daily by mouth for six months, and the treatment was found to be safe and well-tolerated. When compared with a placebo, patients in the treatment group experienced lessening of symptoms such as swollen joints, tenderness, pain and decreased mobility. Improvement was particularly significant at the fol low up visits, indicating a lasting effect of the drug.

The first two trials of dnaJP1 have not raised any significant safety concerns and offer an improved treatment option for patients with rheumatoid arthritis, especially while taking into consideration the side effects associated with current available therapy. The researchers intend to get approval and funding to move into Phase III clinical trials.

This is a very exciting and novel therapeutic approach, which holds the promise to be an entirely new type of immunomodulatory drug – one that can shape a patient’s immune system, rather than suppressing it. With such an advance, the treatment of rheumatoid arthritis seems a potential reachable realit.
'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/20/2017)... Boston, MA and Orlando, FL (PRWEB) , ... ... ... Strohbusch, Orbita PR Director, beth[at]orbitahealth[dot]com, +1 (414) 213-8818 , Orbita, Inc., a leading ... ™, a complete software-as-a-service solution for increasing patient engagement and optimizing care journey ...
(Date:2/20/2017)... Plano, Texas (PRWEB) , ... February 20, 2017 ... ... vital signs technology, welcomes you to stop by for a visit this week ... IT professionals, clinicians and executives from around the globe. Sensogram will be featured ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... Chuck E. ... Sensory Sensitive Sundays, a joint event at Chuck E. Cheese’s locations throughout New England, ... other special needs, the opportunity to experience the fun of visiting Chuck E. Cheese’s ...
(Date:2/19/2017)... ... , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively for ... logo with a glitch reveal in just a few clicks of a mouse. Customizable glitch ... each preset. Use these presets to add a uniquely animated logo to any photos or ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken ... Stairlift and other Butler products. Ken was impressed with the safety and reliability ... endorse the product on his show. This endorsement by Ken Matthews can be ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... LONDON , February 20, 2017 Acute, Chronic ... is expected to grow at a CAGR of 7% from 2016-2021 and ... a CAGR of 6% from 2016 to 2027. The market is estimated ... ... Read on to discover how you can exploit the future business ...
(Date:2/19/2017)... , February 18, 2017 ... agreement to purchase a Medical Delivery Service with the ... cannabis transactions between qualified patients and caregivers. The delivery ... , located in the Coachella Valley, California ... Greater Los Angeles area to the West, ...
(Date:2/18/2017)... , Feb. 17, 2017 Research and Markets ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
Breaking Medicine Technology: